Johnson & Johnson and Bayer, the makers of the anticoagulant medication Xarelto, face a recent hematoma from Xarelto lawsuit in Louisiana federal court joining a growing multidistrict litigation (MDL) against the companies.

Plaintiff Benjamin J. files the hematoma from Xarelto lawsuit, alleging he suffered from severe adverse effects and complications after taking Xarelto. The lawsuit was filed on April 25, 2018.

According to the hematoma from Xarelto lawsuit, Benjamin, a resident and citizen of Albany in Dougherty County, Ga., says that he was prescribed Xarelto on or about Aug. 20, 2015. The medication was prescribed to him to reduce his risks for developing stroke and systemic embolism, the lawsuit maintains.

However, he says he later suffered hematoma and anemia as a direct result of being prescribed Xarelto. It was on June 2, 2016 that he was admitted to Phoebe Putney Memorial Hospital. During his stay, he claims, he received medical treatment that included a blood transfusion.

According to the hematoma from Xarelto lawsuit, some of the harms and damages Benjamin suffered included severe pain and suffering. He also allegedly incurred past and future medical expenses.

The hematoma from Xarelto lawsuit was filed on multiple counts including negligence, strict products liability, breach of express warranty, breach of implied warranty, fraudulent misrepresentation, fraudulent concealment, and negligent misrepresentation.

Benjamin demands a trial by jury.

Overview: Hematoma from Xarelto

Many patients who have endured severe adverse side effects such as severe bleeding, hematoma, or stroke, have been eligible to file lawsuits against Xarelto’s manufacturers, Johnson & Johnson and Bayer. There are currently 20,000 Xarelto lawsuits filed against the companies.

Settlements received have assisted injured patients with both financial and non-financial losses. Some non-financial losses include pain and suffering, while some financial losses have included added medical bills and expenses.

Thousands of patients who have suffered extreme bleeding side effects and/or other side effects have filed lawsuits against the companies. Some of the side effects linked to Xarelto have included:

• Retinal hemorrhages
• Abdominal hemorrhages
• Intracranial hemorrhages
• Adrenal bleeding
• Excessive blood loss
• Epidural hematoma
• Stroke
• Wound infection and complication
• Death

In addition to severe adverse side effects, many patients allege Xarelto’s manufacturers failed to inform patients of these risks through sufficient and adequate warning labels.

Many patients report being left in the dark and completely unaware that Xarelto lacked a reversal agent, a drug that could reverse side effects of internal bleeding in cases in which they occur. This is unlike warfarin, in which internal bleeding side effects may be reversed through the administration of vitamin K.

Xarelto became approved by the U.S. Food and Drug administration (FDA) in 2011. It was approved to treat conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots.

The Hematoma from Xarelto Lawsuit is Case No. 2:18-cv-04215-EEF-MBN, in the U.S. District Court for the Eastern District of Louisiana. The Xarelto MDL is in re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.